Priorities for developing respiratory syncytial virus vaccines in different target populations

See allHide authors and affiliations

Science Translational Medicine  18 Mar 2020:
Vol. 12, Issue 535, eaax2466
DOI: 10.1126/scitranslmed.aax2466

Article Information

vol. 12 no. 535

Print ISSN: 
Online ISSN: 
  • Received for publication March 7, 2019
  • Accepted for publication September 25, 2019
  • .

Author Information

  1. Simon B. Drysdale1,2,*,
  2. Rachael S. Barr3,
  3. Christine S. Rollier1,
  4. Christopher A. Green1,
  5. Andrew J. Pollard1,4 and
  6. Charles J. Sande1,5,*
  1. 1Oxford Vaccine Group, Department of Paediatrics and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK.
  2. 2Institute of Infection and Immunity, St George’s, University of London, London SW17 0RE, UK.
  3. 3Taunton and Somerset NHS Foundation Trust, Taunton TA1 5DA, UK.
  4. 4Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
  5. 5KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya.
  1. *Corresponding author. Email: simon.drysdale{at} (S.B.D.); csande{at} (C.J.S.)


Article usage

Article usage: March 2020 to October 2020

Mar 20202115184172
Apr 20204425586
May 20202074941
Jun 20201813239
Jul 20201372619
Aug 2020115127
Sep 20201723035
Oct 20201122712

Stay Connected to Science Translational Medicine